Ligand Pharmaceuticals Incorporated
US ˙ NasdaqGM ˙ US53220K5048

SecurityLGND / Ligand Pharmaceuticals Incorporated
InstitutionUBS Group AG
Latest Disclosed Ownership104,580 shares
Latest Disclosed Value $ 20,879,398
UBS Group AG ownership in LGND / Ligand Pharmaceuticals Incorporated

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 104,580 shares of Ligand Pharmaceuticals Incorporated (US:LGND) valued at $20,879,397 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 143,067 shares of Ligand Pharmaceuticals Incorporated. This represents a change in shares of -26.90% during the quarter. The current value of the position is $24,513,552 USD.

UBS Group AG has a history of taking positions in derivatives of the underlying security (LGND) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

LGND / Ligand Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 104,580 -38,487 -26.90 20,879 -22.81 0.0006
2026-01-29 2025-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 143,067 31,081 27.75 27,050 36.36 0.0044
2025-11-13 2025-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 111,986 78,476 234.19 19,837 420.79 0.0031
2025-08-14 2025-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 33,510 3,074 10.10 3,809 19.03 0.0007
2025-05-13 2025-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 30,436 3,331 12.29 3,200 10.19 0.0006
2025-02-14 2024-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 27,105 15,608 135.76 2,904 152.52 0.0005
2024-11-14 2024-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 11,497 -27,289 -70.36 1,151 -64.81 0.0003
2024-08-14 2024-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 38,786 5,723 17.31 3,268 35.26 0.0008
2024-05-13 2024-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 33,063 14,036 73.77 2,417 77.91 0.0006
2024-02-09 2023-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 19,027 12,111 175.12 1,359 228.02 0.0004
2023-11-09 2023-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 6,916 -1,159 -14.35 414 -28.87 0.0001
2023-08-11 2023-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 8,075 6,894 583.74 582 576.74 0.0002
2023-05-12 2023-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,181 -479 -28.86 87 -21.82 0.0000
2023-02-08 2022-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,660 1,300 361.11 111 254.84 0.0000
2022-11-10 2022-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 360 -310 -46.27 31 -48.33 0.0000
2022-08-10 2022-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 670 -30,614 -97.86 60 -98.30 0.0000
2022-05-16 2022-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 31,284 4,416 16.44 3,520 -15.18 0.0012
2022-02-14 2021-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 26,868 -74 -0.27 4,150 10.58 0.0012
2021-11-15 2021-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 26,942 17,319 179.98 3,753 197.39 0.0012
2021-08-13 2021-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 9,623 5,869 156.34 1,262 120.24 0.0004
2021-05-12 2021-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 3,754 -1,467 -28.10 573 10.40 0.0002
2021-02-11 2020-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 5,221 397 8.23 519 12.83 0.0002
2020-11-12 2020-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 4,824 -2,755 -36.35 460 -45.75 0.0002
2020-07-31 2020-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 7,579 3,241 74.71 848 169.21 0.0004
2020-05-01 2020-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 4,338 -8,702 -66.73 315 -76.84 0.0001
2020-02-14 2019-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 13,040 -36,912 -73.89 1,360 -72.65 0.0005
2019-11-14 2019-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 49,952 38,757 346.20 4,972 289.05 0.0019
2019-08-14 2019-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 11,195 -24,157 -68.33 1,278 -71.24 0.0005
2019-05-14 2019-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 35,352 -11,056 -23.82 4,444 -29.43 0.0018
2019-02-14 2018-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 46,408 7,921 20.58 6,297 -40.39 0.0029
2018-11-14 2018-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 38,487 18,899 96.48 10,564 160.33 0.0042
2018-08-14 2018-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 19,588 -42,566 -68.48 4,058 -60.47 0.0018
2018-05-15 2018-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 62,154 51,166 465.65 10,265 582.06 0.0044
2018-02-14 2017-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 10,988 -16,213 -59.60 1,505 -59.37 0.0006
2017-11-14 2017-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 27,201 -11,838 -30.32 3,704 -21.84 0.0017
2017-11-14 2017-06-30 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 39,039 20,258 107.86 4,739 138.38 0.0025
2017-08-14 2017-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 39,039 20,258 4,739
2017-11-14 2017-03-31 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 18,781 -37,743 -66.77 1,988 -65.38 0.0011
2017-05-12 2017-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 18,781 -37,743 1,988
2017-02-14 2016-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 56,524 27,962 97.90 5,743 97.02 0.0032
2016-11-14 2016-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 28,562 -18,116 -38.81 2,915 -47.64 0.0017
2016-08-12 2016-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 46,678 34,560 285.20 5,567 328.89 0.0035
2016-05-12 2016-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 12,118 -54,744 -81.88 1,298 -82.10 0.0009
2016-02-16 2015-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 66,862 34,324 105.49 7,250 160.04 0.0047
2015-11-13 2015-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 32,538 7,487 29.89 2,788 10.28 0.0020
2015-08-14 2015-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 25,051 2,003 8.69 2,528 42.26 0.0017
2015-05-14 2015-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 23,048 14,635 173.96 1,777 296.65 0.0012
2015-02-17 2014-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 8,413 8,413 448 0.0003
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2021-11-15 2021-09-30 13F LIGAND PHARMACEUTICALS COM NEW Call 0 -100.00 0 -100.00 n/a n/a n/a
2021-08-13 2021-06-30 13F LIGAND PHARMACEUTICALS COM NEW Call 9,000 -43.75 1,181 -51.58 n/a n/a n/a
2021-05-12 2021-03-31 13F LIGAND PHARMACEUTICALS COM NEW Call 16,000 2,439 n/a n/a n/a
2021-02-11 2020-12-31 13F LIGAND PHARMACEUTICALS COM NEW Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-11-12 2020-09-30 13F LIGAND PHARMACEUTICALS COM NEW Call 5,200 496 n/a n/a n/a
2020-07-31 2020-06-30 13F LIGAND PHARMACEUTICALS COM NEW Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-05-01 2020-03-31 13F LIGAND PHARMACEUTICALS COM NEW Call 10,500 -82.50 764 -87.79 n/a n/a n/a
2020-02-14 2019-12-31 13F LIGAND PHARMACEUTICALS COM NEW Call 60,000 263.64 6,257 281.06 n/a n/a n/a
2019-11-14 2019-09-30 13F LIGAND PHARMACEUTICALS COM NEW Call 16,500 1,642 n/a n/a n/a
2015-05-14 2015-03-31 13F LIGAND PHARMACEUTICALS COM NEW Call 0 -100.00 0 -100.00 n/a n/a n/a
2015-02-17 2014-12-31 13F LIGAND PHARMACEUTICALS COM NEW Call 200 11 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2021-08-13 2021-06-30 13F LIGAND PHARMACEUTICALS COM NEW Put 0 -100.00 0 -100.00 n/a n/a n/a
2021-05-12 2021-03-31 13F LIGAND PHARMACEUTICALS COM NEW Put 76,300 128.44 11,632 250.15 n/a n/a n/a
2021-02-11 2020-12-31 13F LIGAND PHARMACEUTICALS COM NEW Put 33,400 3,322 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.